argenx (NASDAQ:ARGX) Issues Quarterly Earnings Results

argenx (NASDAQ:ARGX - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.33), Zacks reports. The firm had revenue of $412.51 million during the quarter, compared to analysts' expectations of $404.03 million. argenx had a negative net margin of 23.26% and a negative return on equity of 16.97%. During the same quarter in the previous year, the firm posted ($0.52) EPS.

argenx Stock Performance

NASDAQ ARGX traded down $7.92 on Friday, reaching $374.63. 369,022 shares of the company's stock traded hands, compared to its average volume of 311,647. The stock has a 50 day moving average price of $383.02 and a 200-day moving average price of $410.32. The firm has a market cap of $22.26 billion, a price-to-earnings ratio of -73.09 and a beta of 0.67. argenx has a fifty-two week low of $327.73 and a fifty-two week high of $550.76.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Robert W. Baird reduced their price target on argenx from $505.00 to $490.00 and set an "outperform" rating on the stock in a research note on Friday, March 1st. Wolfe Research began coverage on argenx in a research note on Thursday, February 15th. They set a "peer perform" rating for the company. Wells Fargo & Company raised their price target on argenx from $472.00 to $478.00 and gave the company an "overweight" rating in a report on Tuesday, February 20th. Truist Financial lifted their target price on shares of argenx from $370.00 to $440.00 and gave the stock a "buy" rating in a report on Tuesday, March 5th. Finally, Wedbush reissued an "outperform" rating and set a $521.00 price target on shares of argenx in a research report on Thursday, April 18th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, argenx has a consensus rating of "Moderate Buy" and a consensus target price of $527.84.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.